On-X Life Technologies, Inc. Release: Story Predicting Long-Term Costs of Heart Valve Replacement Study to be Presented at American College of Cardiology Meeting
Published: Mar 08, 2013
The key findings of the study indicate that for a typical 55-year-old heart valve disease patient with a 25-year life expectancy who requires a heart valve replacement, the cumulative healthcare cost savings of using the On-X mechanical valve instead of a stented tissue valve for the initial surgery is approximately $60,000. Extrapolating on that rate for the estimated 20,000 patients in this age group presently receiving stented tissue valves would provide a total U.S. healthcare cost savings of approximately $1.2 billion per year.
According to Dr. Culler, “This analysis has taken into consideration costs associated with and documented by peer-reviewed publications. These costs include the implantation and lifetime maintenance of the study heart valves, including the cost of treatment of complications for each prosthesis and reoperation over time for stented tissue valves. It is our hope that this analysis may help provide insight into future costs as one aspect of the prosthesis choice decision.”
From a more clinical viewpoint, Dr. Levitsky commented, “Several recent studies suggest significant mortality benefits for patients receiving mechanical valves in comparisons of matched patient groups. This analytical construct demonstrates cost savings if a mechanical valve such as the On-X valve is used for the initial implantation.”
“It was important for On-X LTI to support this cost analysis,” said Clyde Baker, On-X LTI’s president. “The future of healthcare will likely be one of purchasing value through comparative cost effectiveness. We believe the On-X valve with its documented lower complications and anticipated reduction in anticoagulation therapy requirements is the ideal valve for many younger patients.”
On-X heart valves are made of pure On-X Carbon and have an advanced design that causes less blood cell damage than traditional mechanical valves. Long-term studies have documented fewer morbid events in recipients of On-X valves. Presently, the Prospective Randomized On-X Valve Reduced Anticoagulation Clinical Trial (PROACT) is examining if patients may require less anticoagulation.
The On-X valve is the result of a breakthrough in medical grade carbon technology On-X pure pyrolytic carbon. In addition to providing a more thromboresistant surface, the comparatively high strength of pure On-X Carbon® enabled On-X LTI to make significant valve design changes that resulted in a prosthesis that acts more like a natural valve in its treatment of blood. It is well documented that the On-X valve does not produce the turbulence and blood damage commonly produced by other mechanical heart valve prostheses and, therefore, significantly reduces the potential for life-threatening blood clots.
About On-X LTI
On-X® Life Technologies, Inc. (On-X LTI) develops heart valve replacements that significantly improve the quality of life of patients. Jack Bokros, Ph.D., and his associates founded On-X LTI in 1994 to further advance prosthetic heart valve technology by capitalizing on their new form of pyrolytic carbon. The company has FDA, CE and Japanese approval for sale of the On-X® valve. On-X LTI also provides contract manufacturing services utilizing its patented pyrolytic carbon to manufacturers of other medical products, including orthopedic joint and spine prostheses. Headquartered in Austin, Texas, On-X LTI is a privately held company.
More information is located at www.onxlti.com.